Abstract
Ankylosing spondylitis (AS) is a chronic inflammatory disorder of the spine that can lead to significant disability if left untreated. Although conventional treatments can be successful in alleviating symptoms, they have not been shown to stop progression of the disease. The proinflammatory cytokine tumor necrosis factor (TNF) is central to the pathogenesis of AS. Several TNF-α blocker drugs such as infliximab, adalimumab, etanercept and golimumab have been developed and shown to control symptoms effectively, possibly preventing both clinical and radiographic progression of the disease in patients with AS. Acute inflammatory lesions in the spine and sacroiliac joints can be effectively suppressed by the TNF-α blockers in AS, suggesting that bone destruction and bone proliferation might be prevented.
Keywords: Ankylosing spodylitis, biologic agents, TNF blockers, treatment
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Title: Treatment of Ankylosing Spondylitis with Biologic Agents
Volume: 9 Issue: 1
Author(s): Mehmet Tuncay Duruoz
Affiliation:
- CBU Medical School, PMR Department, Rheumatology Division, Manisa, Turkey.,Turkey
Keywords: Ankylosing spodylitis, biologic agents, TNF blockers, treatment
Abstract: Ankylosing spondylitis (AS) is a chronic inflammatory disorder of the spine that can lead to significant disability if left untreated. Although conventional treatments can be successful in alleviating symptoms, they have not been shown to stop progression of the disease. The proinflammatory cytokine tumor necrosis factor (TNF) is central to the pathogenesis of AS. Several TNF-α blocker drugs such as infliximab, adalimumab, etanercept and golimumab have been developed and shown to control symptoms effectively, possibly preventing both clinical and radiographic progression of the disease in patients with AS. Acute inflammatory lesions in the spine and sacroiliac joints can be effectively suppressed by the TNF-α blockers in AS, suggesting that bone destruction and bone proliferation might be prevented.
Export Options
About this article
Cite this article as:
Duruoz Tuncay Mehmet, Treatment of Ankylosing Spondylitis with Biologic Agents, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 2010; 9(1) . https://dx.doi.org/10.2174/187152310790711674
DOI https://dx.doi.org/10.2174/187152310790711674 |
Print ISSN 1871-5230 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-614X |

- Author Guidelines
- Editorial Policies
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Allegations from Whistleblowers
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Reviewer Guidelines
- Guest Editor Guidelines
- Board Recruitment Workflow
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Can We Extrapolate Data from One Immune-Mediated Inflammatory Disease to Another One?
Current Medicinal Chemistry Tumor Necrosis Factor Blocking Therapy and Congestive Heart Failure in Patients with Inflammatory Rheumatic Disorders: A Systematic Review
Current Medicinal Chemistry Intestinal Microbiota: A Regulator of Intestinal Inflammation and Cardiac Ischemia?
Current Drug Targets Rheumatic Manifestations Associated with Inflammatory Bowel Diseases
Current Rheumatology Reviews Early Diagnosis of AS or Other SpA - From Clinical and Radiologic Viewpoint
Current Rheumatology Reviews HLA-B27 and B27-Subtypes in the Pathogenesis of Ankylosing Spondylitis
Current Rheumatology Reviews Biologics in Inflammatory and Immunomediated Arthritis
Current Pharmaceutical Biotechnology Ankylosing Spondylitis, HLA-B27, Klebsiella and “Popper Sequences”
Current Rheumatology Reviews Functional Variants of the Interleukin-23 Receptor Gene in Non-Gastrointestinal Autoimmune Diseases
Current Medicinal Chemistry Central Nervous System Involvement in Pediatric Rheumatic Diseases: Current Concepts in Treatment
Current Pharmaceutical Design Patient Attitudes Toward Western Medicine and the Future of Chinese Medicine for Spondyloarthritis
Current Rheumatology Reviews Effects of the Disease Characteristics and the Treatment on Psychological Status in Patients with Rheumatoid Arthritis and Ankylosing Spondylitis
Current Rheumatology Reviews The Association Between Genes and SpA in Asian
Current Rheumatology Reviews The Role of Autophagy in Rheumatic Disease
Current Drug Targets Pathogenesis and Biomarkers in Spondyloarthritis: Clues from Microarray Analyses
Current Rheumatology Reviews Inflammatory Mediators as Potential Therapeutic Targets in the Spine
Current Drug Targets - Inflammation & Allergy HLA and Non-HLA Genes in Ankylosing Spondylitis and Seronegative Spondyloarthritis in Asia
Current Rheumatology Reviews Demographic Characteristic of Ankylosing Spondylitis in Chinese
Current Rheumatology Reviews Excess Cardiovascular Risk in Inflammatory Rheumatic Diseases: Pathophysiology and Targeted Therapy
Current Pharmaceutical Design Physiotherapy for Ankylosing Spondylitis: Systematic Review and a Proposed Rehabilitation Protocol
Current Rheumatology Reviews